News

AI, Isomorphic and Google

Alphabet’s Isomorphic Labs has grand ambitions to ‘solve all diseases’ with AI. Now, it’s gearing up for its first human trials
One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.
Human trials for Google’s drugs made by AI set to begin soon, possibly changing how we perceive healthcare
Isomorphic Labs is preparing to test AI-designed drugs in humans, marking a new phase in drug development with artificial intelligence. (Unsplash) Google DeepMind's somewhat secretive spinoff, Isomorphic Labs,
Google-backed Isomorphic Labs to launch human trials for AI-designed drugs
Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.
Google’s Secret Moonshot Project Gears Up For Human Trail Of AI-Designed Drugs
Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The hitherto lesser-known Google subsidiary aims to revolutionize drug development by using advanced AI to create medicines more quickly, affordably, and accurately than traditional methods.
Google’s AI-designed drugs to enter human trials this year
Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling breakthroughs.
Google DeepMind ready to start human trials of AI-designed drugs; company exec says, ‘We’re getting very close’
Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in pharmaceutical innovation.
Isomorphic Labs: AI-Created Drugs Move Closer to Human Trials
A Isomorphic Labs, a drug discovery company driven by artificial intelligence (IA) and part of the A (holding of Google), is getting ready to begin the first human clinical trials of their anti-cancer drugs cancer designed by AI. The company’s ultimate goal is to “solve all diseases”.
Google’s Isomorphic Labs “Very Close” To Starting Human Trials For AI-Generated Medicines
Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And his company is on track to put these words into practice. Isomorphic Labs,
Google Ready To Start Human Trials Of Its AI-Designed Drugs
Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.
Google’s AI-designed cancer drug may soon enter human trials, says DeepMind exec
Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in fields like cancer and immunology using artificial intelligence.
An AI That Promises to “Solve All Diseases” Is About to Test Its First Human Drugs
A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...
Research Snipers20h
Google daughter wants to heal “all diseases” with AI
Google Deepmind’s offshoot Isomorphic Labs is about to be a milestone: The first AI developed medication should go into the ...
Hosted on MSN1d
AI-powered drug company spun out of Google’s DeepMind says human trials are ‘very close’
Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to ...
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is…'
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...
Business Today1d
Google's secret weapon against cancer might be an AI algorithm
Alphabet’s AI-powered drug discovery company, Isomorphic Labs, is preparing to take its first major leap into the real world. After years of development, the company says it’s now gearing up for ...